Discovery - University of Dundee - Online Publications

Library & Learning Centre

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

Research output: Contribution to journalArticle

View graph of relations

Authors

  • Sabita S. Soedamah-Muthu
  • Val Charlton-Menys
  • Weihang Bao
  • Casper Schalkwijk
  • Coen D. A. Stehouwer
  • Helen M. Colhoun
  • D. John Betteridge
  • Paul N. Durrington
  • Graham A. Hitman
  • H. Andrew W. Neil
  • Shona J. Livingstone
  • John H. Fuller
  • David A. DeMicco
  • Gregory M. Preston

Research units

Info

Original languageEnglish
Pages288-297
Number of pages10
JournalBritish Journal of Diabetes and Vascular Disease
Journal publication date2011
Volume11
Issue6
DOIs
StatePublished

Abstract

We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)a, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFa, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70% were men. TNFa 2.20 pg/mL (1.82-2.86), sVCAM-1 865 ng/mL (729-1059) and sICAM-1 619 ng/mL (533-753) concentrations (median, interquartile range 25, 75%) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95% confidence interval (CI) 0.66-1.0) and 0.59 (95% CI 0.50-0.71), respectively. In conclusion atorvastatin had no significant effect on TNFa, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD. © SAGE Publications 2011.

Documents

Library & Learning Centre

Contact | Accessibility | Policy